Chemoinformaics analysis of 1-[(E)-HEX-1-ENYL]CYCLOHEXAN-1-OL
| Molecular Weight | 182.307 | nRot | 4 |
| Heavy Atom Molecular Weight | 160.131 | nRig | 0 |
| Exact Molecular Weight | 182.167 | nRing | 1 |
| Solubility: LogS | 0.281 | nHRing | 0 |
| Solubility: LogP | 0.903 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 35 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 12 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 35.5114 |
| nHD | 1 | BPOL | 22.0706 |
| QED | 0.565 |
| Synth | 2.609 |
| Natural Product Likeliness | -0.051 |
| NR-PPAR-gamma | 0.013 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.028 |
| HIA | 0.002 |
| CACO-2 | -4.29 |
| MDCK | 0.0000384 |
| BBB | 0.574 |
| PPB | 0.207039 |
| VDSS | 1.265 |
| FU | 0.681585 |
| CYP1A2-inh | 0.031 |
| CYP1A2-sub | 0.284 |
| CYP2c19-inh | 0.029 |
| CYP2c19-sub | 0.589 |
| CYP2c9-inh | 0.013 |
| CYP2c9-sub | 0.061 |
| CYP2d6-inh | 0.003 |
| CYP2d6-sub | 0.09 |
| CYP3a4-inh | 0.008 |
| CYP3a4-sub | 0.183 |
| CL | 7.405 |
| T12 | 0.708 |
| hERG | 0.201 |
| Ames | 0.08 |
| ROA | 0.028 |
| SkinSen | 0.362 |
| Carcinogencity | 0.308 |
| EI | 0.984 |
| Respiratory | 0.013 |
| NR-Aromatase | 0.053 |
| Antiviral | Yes |
| Prediction | 0.594887 |